ValueScreener

ValueScreener company report

Sangrix Inc. (SGRX)

NASDAQ / Financial Services / Finance Services

Share price

0.69 USD Market dataClose of Oct 15, 2026

Market capitalisation

548.0K USD Market dataClose of Oct 15, 2026
Market data
Oct 15, 2026
Filed accounts
FY2026, filed Sep 18, 2026
Ratios computed
Oct 15, 2026
Filed years
10, FY2017 to FY2026
Four kinds of sourceSEC filingCompany statementMarket dataComputedWhat each means
SEC filingFiled with the SEC
Read from a statement the company filed with the SEC, with the form, fiscal year, filing date and accession beside it.
Company statementCompany statement
What the company says about itself in a filing: an 8-K item, the auditor, its own segment names.
Market dataMarket data
Prices, market value and what analysts publish, with the date they are as of.
ComputedComputed by ValueScreener
Worked out by us from the other three, with the inputs and the formula one press away. A score is a research output, not a rating or a recommendation.
Reading

1 of 10

Overview

What the business is, what it costs, and how it reads on four questions.

Market dataSEC filingComputed

Four questions, at a glance

Quality

Return on equity

-254.3% Computed

From the FY2026 filing

Read quality

Valuation

Price to book

0.10x Computed

FY2026 accounts, priced at the latest close

Read valuation

Cash generation

Free cash flow yield

n/a Computed

FY2026 accounts, priced at the latest close

Why n/a

We do not hold this figure for this company, so there is nothing to show.

Read cash generation

Revenue and net income, as filed

FY2017 Revenue: 63.3M USDFY2017 Net income: 2.5M USDFY2018 Revenue: 101.1M USDFY2018 Net income: 3.8M USDFY2019 Revenue: 99.1M USDFY2019 Net income: 4.4M USDFY2020 Revenue: 24.2M USDFY2020 Net income: -4.9M USDFY2021 Revenue: 80.5M USDFY2021 Net income: -45.6M USDFY2022 Revenue: 6.3M USDFY2022 Net income: 3.2M USDFY2023 Revenue: 6.3M USDFY2023 Net income: -28.2M USDFY2024 Revenue: 2.9M USDFY2024 Net income: -17.5M USDFY2025 Revenue: 39.5K USDFY2025 Net income: -4.4M USDFY2026 Net income: -14.3M USD
Revenue Net income10 filed fiscal years, from the annual reports; the table in Filings names each document.
Named tests met
1 of 30 Which tests
The business, and the score behind its five axes

The reading, in brief

Is it good

Return on equity was -254.3% in FY2026, in the band labelled "Likely below the cost of equity" (below 8.0%), on lines anchored on Damodaran's cost-of-capital data, suggesting returns on shareholders' money below the usual cost of equity.

Today, against the Financial Services sector (739 companies), -254.3% sits at the 2nd percentile; the middle half of that group runs from 3.6% to 13.7%.

Is it safe

Current ratio was 6.98 in FY2026, in the band labelled "At or above Graham's requirement" (2.00 and above), on lines anchored on Graham's defensive-investor criteria, suggesting short-term assets well above short-term obligations.

Today, against the Financial Services sector (274 companies), 6.98 sits at the 79th percentile; the middle half of that group runs from 0.97 to 5.71.

Year by year against peers
Whether Sangrix Inc.'s return on equity stayed above the median of the Financial Services sector, year by year. (FY2022 to FY2025, 4 fiscal years of Sangrix Inc. with a comparable figure)
The direction
Which way Sangrix Inc.'s gross margin has moved, and how steadily. (FY2017 to FY2025, 9 filed years of Sangrix Inc.)
What could explain it
What in Sangrix Inc.'s filed statements could explain the movements. (2 readings drawn from the statement lines Sangrix Inc. filed)
What to check next
What to check next on Sangrix Inc., and where in its filings. (1 question for Sangrix Inc.)
In one paragraph
One paragraph on Sangrix Inc.'s returns, cash, balance sheet and price. (2 of sixteen figures read for Sangrix Inc.)

These are SGRX’s filed figures. The research desk says what they mean, against peers and its own years, with what to check next.

Research SGRXPart of Serious. New accounts start with 30 days of Professional, free, no card.

2 of 10

What changed

The newest filing, what it moved, and when the next one is due.

SEC filingCompany statement

The newest accounts on file are the FY2026 annual report: 20-F, filed Sep 18, 2026, accession 0001104659-26-108989.

3 of 10

Quality

The returns the business earns on its capital, and the margins behind them.

SEC filingComputed

Sangrix Inc: returns on capital and margins, each with its source
FigureValue, source and document
Return on invested capital, after tax
Why n/a

The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.

n/a ComputedFY2026 20-F, filed Sep 18, 2026, 0001104659-26-108989
Return on equity-254.3% ComputedFY2026 20-F, filed Sep 18, 2026, 0001104659-26-108989
Return on capital employed, pre-tax-72.5% ComputedFY2026 20-F, filed Sep 18, 2026, 0001104659-26-108989
Return on assets-67.5% ComputedFY2026 20-F, filed Sep 18, 2026, 0001104659-26-108989
Gross margin
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedFY2026 20-F, filed Sep 18, 2026, 0001104659-26-108989
Operating margin
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedFY2026 20-F, filed Sep 18, 2026, 0001104659-26-108989
Net margin
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedFY2026 20-F, filed Sep 18, 2026, 0001104659-26-108989

4 of 10

Financial strength

What it owes against what it owns, and whether it can meet what falls due.

SEC filingComputedCompany statement

Sangrix Inc: leverage, liquidity and distress, each with its source
FigureValue, source and document
Debt to equity
Why n/a

The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.

n/a ComputedFY2026 20-F, filed Sep 18, 2026, 0001104659-26-108989
Current ratio6.98 ComputedFY2026 20-F, filed Sep 18, 2026, 0001104659-26-108989
Quick ratio6.98 ComputedFY2026 20-F, filed Sep 18, 2026, 0001104659-26-108989
Interest coverage
Why n/a

No interest expense is filed for this year, so coverage is not computed.

n/a ComputedFY2026 20-F, filed Sep 18, 2026, 0001104659-26-108989
Altman Z-score
Why n/m

Altman's Z-Score was estimated on manufacturers and explicitly excludes financial firms. A financial company scores in the distress zone by construction, so the number would be wrong rather than alarming. Not applicable to financials.

n/m ComputedClose of Oct 15, 2026 · FY2026 20-F, filed Sep 18, 2026, 0001104659-26-108989
Net debt
Why n/a

The FY2026 balance sheet carries no net debt we could read.

n/a ComputedFY2026 20-F, filed Sep 18, 2026, 0001104659-26-108989
Total assets 21.2MTotal liabilities 12.1MShareholders' equity 5.6MOwnsOwes, and equity
Total assets Total liabilities Shareholders’ equity
The balance sheet, line by line

Financial health

What Sangrix Inc owned and owed at the end of fiscal 2026, from the balance sheet it filed (20-F, filed Sep 18, 2026, 0001104659-26-108989).

Sangrix Inc: balance sheet position
Total assets21.2M FiledFY2026 20-F, filed Sep 18, 2026
Total liabilities12.1M FiledFY2026 20-F, filed Sep 18, 2026
Shareholders' equity5.6M FiledFY2026 20-F, filed Sep 18, 2026
Cash1.6M FiledFY2026 20-F, filed Sep 18, 2026
Total debtn/a FiledFY2026 20-F, filed Sep 18, 2026
Net debtn/a
Current ratio6.98
Debt to equityn/a
  • Debt to equity: FY2026: The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
  • Interest cover: FY2026: No interest expense is filed for this year, so coverage is not computed.

Read from the filed balance sheet for each year, with the income statement of the same year supplying operating profit where a ratio needs it. Nothing here is a view on whether this company is sound.

5 of 10

Valuation context

What the market charges for it, against its own record and companies like it.

Market dataSEC filingComputed

Sangrix Inc: what the market charges, each with its source
FigureValue, source and document
Price to earnings
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedClose of Oct 15, 2026 · FY2026 20-F, filed Sep 18, 2026, 0001104659-26-108989
P/E on trailing twelve months
Why n/a

A trailing figure needs 4 filed quarters with the dates they were filed on, and we hold 0 for this company. Nothing is drawn rather than a line built from fewer.

n/a ComputedClose of Oct 15, 2026 · Trailing four quarters, each as known on the day; the quarterly filings are listed under Filings
Price to book0.10x ComputedClose of Oct 15, 2026 · FY2026 20-F, filed Sep 18, 2026, 0001104659-26-108989
Price to sales
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedClose of Oct 15, 2026 · FY2026 20-F, filed Sep 18, 2026, 0001104659-26-108989
Enterprise value to EBIT
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2026 20-F, filed Sep 18, 2026, 0001104659-26-108989
Enterprise value to EBITDA
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2026 20-F, filed Sep 18, 2026, 0001104659-26-108989
Price to earnings over growth
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedClose of Oct 15, 2026 · FY2026 20-F, filed Sep 18, 2026, 0001104659-26-108989
Diluted earnings per share
Why n/a

The FY2026 filing carries no diluted earnings per share we could read.

n/a FiledFY2026 20-F, filed Sep 18, 2026, 0001104659-26-108989
Graham number
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedFY2026 20-F, filed Sep 18, 2026, 0001104659-26-108989

We publish no fair value or price target of our own. Value SGRX on your own assumptions in the DCF workbench, starting from the filed figures.

Its own record, and companies like it

Valuation

What the market charges for Sangrix Inc today, and the multiples it has carried. No value of ours: the figures are the filings’ and the market’s.

Sangrix Inc: valuation
Share price0.69 USD
Market capitalisation548.0K USD
Enterprise value to EBITDAn/a
Graham numbern/m
Diluted earnings per sharen/a

Price to earnings on trailing twelve months: A trailing figure needs 4 filed quarters with the dates they were filed on, and we hold 0 for this company. Nothing is drawn rather than a line built from fewer.

Companies like Sangrix Inc

  1. Alpha Compute Corp (ALP)Market cap 1.7M USD
  2. OpenWorld, Inc. (OPNW)Market cap 3.8M USD
  3. PowerCompute, Inc. (PWCM)Market cap 623.0K USD
  4. Sphere 3D Corp. (DRK)Market cap 18.8M USD
  5. House of Doge Inc. (HODO)Market cap 6.0M USD

Same industry (Finance Services) and size band (Nano, under 50M), nearest in market value and current ratio. Each of those counts equally, by how many of the companies considered sit between the two on it. Closest first: the order is likeness and nothing else.

6 of 10

Cash generation

Whether profit arrives as cash, and what is paid back to shareholders.

Computed

Sangrix Inc: cash generation and what is paid out, each with its source
FigureValue, source and document
Free cash flow yield
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2026 20-F, filed Sep 18, 2026, 0001104659-26-108989
Free cash flow
Why n/a

The FY2026 filing carries no free cash flow we could read.

n/a ComputedFY2026 20-F, filed Sep 18, 2026, 0001104659-26-108989
Free cash flow margin
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedFY2026 20-F, filed Sep 18, 2026, 0001104659-26-108989
Dividend yield
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2026 20-F, filed Sep 18, 2026, 0001104659-26-108989
Payout ratio
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedFY2026 20-F, filed Sep 18, 2026, 0001104659-26-108989
FY2017 Free cash flow: -2.5M USDFY2017 Net income: 2.5M USDFY2018 Free cash flow: -3.7M USDFY2018 Net income: 3.8M USDFY2019 Free cash flow: -5.3M USDFY2019 Net income: 4.4M USDFY2020 Free cash flow: -6.6M USDFY2020 Net income: -4.9M USDFY2021 Net income: -45.6M USDFY2022 Free cash flow: -22.5M USDFY2022 Net income: 3.2M USDFY2023 Free cash flow: -6.9M USDFY2023 Net income: -28.2M USDFY2024 Net income: -17.5M USDFY2025 Net income: -4.4M USDFY2026 Net income: -14.3M USD
Free cash flow Net incomeProfit that arrives as cash stands level with net income; a gap year after year is worth reading about.

7 of 10

Filings

Every figure, the year it is for and the document it was read from.

SEC filing

The filed figures

Computed from the accounts this company filed with the SEC and, in a ratio with a price in it, the last close, dated on this page. Every filed figure below carries the fiscal year and the filing date its accounts were read from, and every blank carries the reason it is blank. Nothing here is a view on this company.

Sangrix Inc.: the eight ratios, with the fiscal year and filing date behind each.
FigureValueYearAs of
n/mFY2026Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
0.10xFY2026Oct 15, 2026
n/aFY2026Oct 15, 2026
n/a Operating profit is zero or negative, so there is no profit for a buyer's price to be a multiple of.
n/aFY2026Oct 15, 2026
n/a The filed cash flow statement reports neither free cash flow nor the operating cash flow and capital spending it is built from.
n/aFY2026Sep 18, 2026
n/a The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
n/aFY2026Oct 15, 2026
n/a The filed cash flow statement reports no dividend paid at all. That is not the same as a filed zero, and we will not read it as one.
n/aFY2026Sep 18, 2026
n/a The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
6.98FY2026Sep 18, 2026
n/aFY2026Oct 15, 2026
n/a Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
n/mFY2026Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
n/mFY2026Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
n/aFY2026Sep 18, 2026
n/a Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
n/aFY2026Sep 18, 2026
n/a Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

The figures are computed from the accounts for fiscal 2026, the newest full year on file. 10 filed fiscal years on record, FY2017 to FY2026, from SEC EDGAR. Prices as of Oct 15, 2026. Ratios recomputed Oct 15, 2026. Two facts, because a recompute is not a fresh quote.

The year and the filing date name the statement each figure’s accounts are read from, and they stand even where the figure itself could not be computed: the line beneath a blank says what that statement did not carry. A figure’s name opens its formula and the filings behind it; a statement that names no SEC filing has no filing date, and reads n/a.

Ten years of filed figures, year by year

Ten years of filed figures

10 filed fiscal years, FY2017 to FY2026, read from the annual reports Sangrix Inc filed with the SEC. Each year names its filing. Amounts in USD, as filed.

Sangrix Inc: revenue, earnings, free cash flow and returns, by fiscal year, with the filing each year was read from
YearRevenueOperating incomeNet incomeEPS, dilutedFree cash flowOperating marginReturn on equityFiling
FY2026n/a-14.3M-14.3Mn/an/an/a-254.3%20-F, Sep 18, 20260001104659-26-108989
FY202539.5K-3.0M-4.4Mn/an/a-7574.9%-112.0%20-F, Oct 31, 20250001104659-25-105009
FY20242.9M-14.8M-17.5Mn/an/a-513.6%-1054.4%20-F, Dec 26, 20240001410578-24-002113
FY20236.3M-28.3M-28.2Mn/a-6.9M-452.1%-275.0%20-F, Oct 31, 20230001410578-23-002160
FY20226.3M-28.3M3.2Mn/a-22.5M-452.1%9.3%20-F, Aug 25, 20220001410578-22-002742
FY202180.5M-3.5M-45.6Mn/an/a-4.3%n/m20-F, Nov 15, 20210001410578-21-000293
FY202024.2M-3.4M-4.9Mn/a-6.6M-14.2%-20.5%20-F, Nov 17, 20200001104659-20-126431
FY201999.1M-511.2K4.4Mn/a-5.3M-0.5%17.8%20-F, Nov 6, 20190001104659-19-060596
FY2018101.1M7.0M3.8Mn/a-3.7M7.0%26.9%20-F, Nov 6, 20190001104659-19-060596
FY201763.3M3.5M2.5Mn/a-2.5M5.6%n/a20-F, Nov 6, 20190001104659-19-060596
  • Revenue, compound annual growth FY2017 to FY2025: -60.2%
  • Earnings: Earnings was not positive in both 2017 and 2026, so a compound rate across the window is not defined. Both figures are in the table.
  • Earnings per share: Fewer than two filed years carry earnings per share.
  • Free cash flow: Free cash flow was not positive in both 2017 and 2023, so a compound rate across the window is not defined. Both figures are in the table.

Every figure in this section is a line of a filed annual statement or a ratio of two of them. Nothing here is estimated or smoothed. Earnings per share filed before a share split are put on today's share count, and say so. Nothing here is a verdict on the company.

8 of 10

Risks and guardrails

The accounting screens, the published tests, and the lines you can set to be told.

ComputedCompany statement

Sangrix Inc: accounting screens and published tests, each with its source
FigureValue, source and document
Beneish M-score
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedFY2026 20-F, filed Sep 18, 2026, 0001104659-26-108989
Piotroski F-score
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedFY2026 20-F, filed Sep 18, 2026, 0001104659-26-108989
Named tests met1 of 30 Computed
Beta0.82 ComputedClose of Oct 15, 2026

The named tests

Of 30 tests value investors published: 1 met, 9 not met, 20 we could not complete. Counts, never a score: a single figure would have to decide that meeting one investor’s criteria and meeting another’s are worth the same.

Which tests, by name(all 30)
Meets
Cheapest quarter on P/B (David Dreman)
Does not
Large cap, low P/E; High returns and growth; Low beta, profitable; Near the 52-week low; Two thirds of NCAV (Benjamin Graham); High returns, low debt; Owner earnings yield; High return on tangibles; Low P/S, rising earnings (James O'Shaughnessy)
Not measured
Defensive investor (Benjamin Graham); Deep value; Earnings yield and ROIC (Joel Greenblatt); High F-score, low P/B (Joseph Piotroski); Three forensic scores; Low PEG, low debt (Peter Lynch); Gross margin, turnover (Robert Novy-Marx); EV/EBITDA and coverage; High yield, low payout; Dividends and buybacks; ROIC at or above WACC; Z-score and coverage (Edward Altman); P/E times P/B (Benjamin Graham); Book or below, low debt (Walter Schloss); Cash-covered dividend; Tangible book or below; Cash-flow yield and ROIC; Clean books, high ROIC; Cheapest quarter on P/E (David Dreman); Low P/E, growth, yield (John Neff). A test with a figure we could not read is incomplete, never met and never failed.
Figures we could not read(26)
  • Current Ratio: Graham set this test for industrial companies.
  • Debt to Equity: The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
  • Positive Earnings Streak: The latest filed year has no per-share earnings we can read; the test needs 10.
  • Piotroski F-Score: Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
  • P/E Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • EV/EBIT: We do not hold this figure for this company, so there is nothing to show.
  • Return on Invested Capital: The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
  • Altman Z-Score: Altman's Z-Score was estimated on manufacturers and explicitly excludes financial firms. A financial company scores in the distress zone by construction, so the number would be wrong rather than alarming. Not applicable to financials.
  • Beneish M-Score: Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
  • PEG Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • Eps Growth 5Y: We do not hold this figure for this company, so there is nothing to show.
  • Rev Growth 5Y: Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
  • Gross Margin: Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
  • Asset Turnover: Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
  • EV/EBITDA: We do not hold this figure for this company, so there is nothing to show.
  • Interest Coverage: No interest expense is filed for this year, so coverage is not computed.
  • Dividend Yield: We do not hold this figure for this company, so there is nothing to show.
  • Payout Ratio: We do not hold this figure for this company, so there is nothing to show.
  • Free Cash Flow Yield: We do not hold this figure for this company, so there is nothing to show.
  • Share Count Change Yoy: We do not hold this figure for this company, so there is nothing to show.
  • ROIC-WACC Spread: We do not hold this figure for this company, so there is nothing to show.
  • Price To Graham: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • Capex To Ocf: We do not hold this figure for this company, so there is nothing to show.
  • P/S Ratio: Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
  • Dividend Coverage Ratio: We do not hold this figure for this company, so there is nothing to show.
  • Dividend Streak: We do not hold this figure for this company, so there is nothing to show.

9 of 10

Declared positions

Whether anybody here owns this company.

Positions declared by Javier Sanz Alvarez: no holding in any company shown here, as of October 3, 2026.

10 of 10

Next step

What to do with what you have read.

A thesis is your reason for owning it, in your words, with the figures that must stay true. Checking those figures every night against the newest filed accounts, and telling you once when one breaks, is what the subscription adds.

More on this company

What this cannot tell you

  • 26 figures could not be read on this company, among them Current Ratio, Debt to Equity, Positive Earnings Streak. Each blank in the table above names the rest, with its reason. 20 named tests come back incomplete because of them, which is neither met nor missed.

And the one that is true of all of it: This is what the numbers say today. It cannot tell you the day one of them stops being true. Nothing here can, because the reasons are not written down.

Running this once is arithmetic on public documents and you are welcome to it. Writing down why you own each company, in your own words and with the numbers that have to stay true for it to hold, and then having those numbers re-checked every night against the newest filed accounts, and against the latest close where a rule watches a price, is Professional, the plan a new account starts on for 30 days, one trial per person. It writes to you the day one breaks, and stays quiet when nothing does. The check runs every night at 23:30 UTC. A filing is picked up the night after it is published.

No card. 30 free days, and nothing is charged unless you choose a plan.

Analyze your own portfolio

ValueScreener · valuescreener.ai · Computed from accounts filed with the SEC by this company, read from EDGAR, and from dated closing prices. On this page a filed figure opens into its formula, its inputs and the statement, fiscal year and filing date it was read from, and a price into the day of its close. A figure that cannot show that trail says so.

A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.

Once a week, what changed in the filings of US-listed companies, why it can matter to a thesis, and what deserves a closer review. Grounded in filings, not market noise.

Site map
  • Android app coming soon
  • iPhone app coming soon
ValueScreener

Discover companies, research each one to its filings, track what matters, and take your work into your own spreadsheet.

ValueScreener is a trading name of Oliva Real Estate Technologies LLC, a Delaware limited liability company. Legal notices: legal@valuescreener.ai. © 2026 Oliva Real Estate Technologies LLC. All rights reserved.

Risk disclaimer. This service is provided for research and education only. Nothing on it is investment advice, a recommendation, or an offer to buy or sell any security. Capital is at risk, and past performance does not indicate future results. Figures come from filed accounts and may be incomplete, delayed or later restated, so verify a number against the filing before you act on it.